Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,26004712,distribution half-life (T(1/2a)),"Kinetics of blood clearance showed that the distribution half-life (T(1/2a)) and elimination half-life (T(1/2 β)) of (99m)Tc-HBIDP are 2.73 and 24.87 min, respectively.",Pharmacokinetic and imaging evaluation of (99m)Tc-HBIDP as a potential bone imaging agent. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26004712/),min,2.73,18080,DB00399,Zoledronate
,26004712,elimination half-life (T(1/2 β)),"Kinetics of blood clearance showed that the distribution half-life (T(1/2a)) and elimination half-life (T(1/2 β)) of (99m)Tc-HBIDP are 2.73 and 24.87 min, respectively.",Pharmacokinetic and imaging evaluation of (99m)Tc-HBIDP as a potential bone imaging agent. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26004712/),min,24.87,18081,DB00399,Zoledronate
,24968029,maximal loading,"Human and murine RBCs have been successfully loaded with Zoledronate by a procedure of hypotonic dialysis and isotonic resealing, obtaining a dose-dependent drug entrapment with a maximal loading of 7.96±2.03, 6.95±3.9 and 7.0±1.89 µmoles of Zoledronate/ml of packed RBCs for human, Swiss and Balb/C murine RBCs, respectively.",Macrophage depletion by free bisphosphonates and zoledronate-loaded red blood cells. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24968029/),µmoles,7.96,66692,DB00399,Zoledronate
,24968029,maximal loading,"Human and murine RBCs have been successfully loaded with Zoledronate by a procedure of hypotonic dialysis and isotonic resealing, obtaining a dose-dependent drug entrapment with a maximal loading of 7.96±2.03, 6.95±3.9 and 7.0±1.89 µmoles of Zoledronate/ml of packed RBCs for human, Swiss and Balb/C murine RBCs, respectively.",Macrophage depletion by free bisphosphonates and zoledronate-loaded red blood cells. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24968029/),µmoles,6.95,66693,DB00399,Zoledronate
,24968029,maximal loading,"Human and murine RBCs have been successfully loaded with Zoledronate by a procedure of hypotonic dialysis and isotonic resealing, obtaining a dose-dependent drug entrapment with a maximal loading of 7.96±2.03, 6.95±3.9 and 7.0±1.89 µmoles of Zoledronate/ml of packed RBCs for human, Swiss and Balb/C murine RBCs, respectively.",Macrophage depletion by free bisphosphonates and zoledronate-loaded red blood cells. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24968029/),µmoles,7.0,66694,DB00399,Zoledronate
,28626914,maximum concentration in bone (Cmax ),"To further evaluate the bone uptake efficiency, the pharmacokinetics of 99m Tc-EMIHPBP was investigated and showed that maximum concentration in bone (Cmax ) was 31.60 ± 0.15%ID/gram after 60 minutes (tmax ).","Synthesis, preclinical, and pharmacokinetic evaluation of a new zoledronate derivative as a promising antiosteoporotic candidate using radiolabeling technique. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28626914/),[%id] / [gram],31.60,78508,DB00399,Zoledronate
,28626914,tmax,"To further evaluate the bone uptake efficiency, the pharmacokinetics of 99m Tc-EMIHPBP was investigated and showed that maximum concentration in bone (Cmax ) was 31.60 ± 0.15%ID/gram after 60 minutes (tmax ).","Synthesis, preclinical, and pharmacokinetic evaluation of a new zoledronate derivative as a promising antiosteoporotic candidate using radiolabeling technique. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28626914/),min,60,78509,DB00399,Zoledronate
,28626914,AUC (0-∞),"Cumulative residence of 99m Tc-EMIHPBP in the bone [AUC (0-∞) (%ID∙min/gram bone)] was 3685.23, mean residence time was 384.354 minutes, and the calculated bone bioavailability was 15.831%.","Synthesis, preclinical, and pharmacokinetic evaluation of a new zoledronate derivative as a promising antiosteoporotic candidate using radiolabeling technique. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28626914/),[%id∙min] / [bone·gram],3685.23,78510,DB00399,Zoledronate
,28626914,mean residence time,"Cumulative residence of 99m Tc-EMIHPBP in the bone [AUC (0-∞) (%ID∙min/gram bone)] was 3685.23, mean residence time was 384.354 minutes, and the calculated bone bioavailability was 15.831%.","Synthesis, preclinical, and pharmacokinetic evaluation of a new zoledronate derivative as a promising antiosteoporotic candidate using radiolabeling technique. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28626914/),min,384.354,78511,DB00399,Zoledronate
,28626914,bone bioavailability,"Cumulative residence of 99m Tc-EMIHPBP in the bone [AUC (0-∞) (%ID∙min/gram bone)] was 3685.23, mean residence time was 384.354 minutes, and the calculated bone bioavailability was 15.831%.","Synthesis, preclinical, and pharmacokinetic evaluation of a new zoledronate derivative as a promising antiosteoporotic candidate using radiolabeling technique. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28626914/),%,15.831,78512,DB00399,Zoledronate
,28626914,bone/blood ratio,Excellent bone uptake can be obtained 1-hour postinjection with high bone/blood ratio of 23.76 detected with gamma counter.,"Synthesis, preclinical, and pharmacokinetic evaluation of a new zoledronate derivative as a promising antiosteoporotic candidate using radiolabeling technique. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28626914/),,23.76,78513,DB00399,Zoledronate
,18625688,terminal half-lives,"Concentrations of radioactivity showed a rapid decline in plasma and noncalcified tissue but only a slow decline in bone, to approximately 50% of peak at 240 days post dose, whereas the terminal half-lives (50-200 days) were similar in bone and noncalcified tissues, suggesting redistribution of drug from the former rather than prolonged retention in the latter.",Biodistribution and plasma protein binding of zoledronic acid. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18625688/),d,50-200,92993,DB00399,Zoledronate
,18625688,fraction of dose excreted,"At 96 h after dose, the fraction of dose excreted was 36% in rat and 60% in dog; 94 to 96% of the excreted radioactivity was found in urine.",Biodistribution and plasma protein binding of zoledronic acid. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18625688/),%,36,92994,DB00399,Zoledronate
,18625688,fraction of dose excreted,"At 96 h after dose, the fraction of dose excreted was 36% in rat and 60% in dog; 94 to 96% of the excreted radioactivity was found in urine.",Biodistribution and plasma protein binding of zoledronic acid. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18625688/),%,60,92995,DB00399,Zoledronate
,18625688,Blood/plasma concentration ratios,"Blood/plasma concentration ratios were 0.52 to 0.59, and plasma protein binding of zoledronic acid was moderate to low in all species.",Biodistribution and plasma protein binding of zoledronic acid. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18625688/),,0.52 to 0.59,92996,DB00399,Zoledronate
,12412821,half-lives,"Zoledronic plasma disposition was multiphasic, with half-lives of 0.2 and 1.4 hours representing an early, rapid decline of concentrations from the end-of-infusion C(max) to < 1% of C(max) at 24 hours postdose and half-lives of 39 and 4526 hours describing subsequent phases of very low concentrations between days 2 and 28 postdose.",Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12412821/),h,0.2,103122,DB00399,Zoledronate
,12412821,half-lives,"Zoledronic plasma disposition was multiphasic, with half-lives of 0.2 and 1.4 hours representing an early, rapid decline of concentrations from the end-of-infusion C(max) to < 1% of C(max) at 24 hours postdose and half-lives of 39 and 4526 hours describing subsequent phases of very low concentrations between days 2 and 28 postdose.",Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12412821/),h,1.4,103123,DB00399,Zoledronate
,12412821,half-lives,"Zoledronic plasma disposition was multiphasic, with half-lives of 0.2 and 1.4 hours representing an early, rapid decline of concentrations from the end-of-infusion C(max) to < 1% of C(max) at 24 hours postdose and half-lives of 39 and 4526 hours describing subsequent phases of very low concentrations between days 2 and 28 postdose.",Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12412821/),h,39,103124,DB00399,Zoledronate
,12412821,half-lives,"Zoledronic plasma disposition was multiphasic, with half-lives of 0.2 and 1.4 hours representing an early, rapid decline of concentrations from the end-of-infusion C(max) to < 1% of C(max) at 24 hours postdose and half-lives of 39 and 4526 hours describing subsequent phases of very low concentrations between days 2 and 28 postdose.",Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12412821/),h,4526,103125,DB00399,Zoledronate
,12412821,AUC0-24 h ratio,AUC0-24 h and C(max) were dose proportional and showed little accumulation (AUC0-24 h ratio between the third and first dose was 1.28).,Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12412821/),,1.28,103126,DB00399,Zoledronate
,12412821,Ae0-24 h,"Urinary excretion of zoledronic acid was independent of infusion duration, dose, or number of doses, showing average Ae0-24 h of 38% +/- 13%, 41% +/- 14%, and 37% +/- 17%, respectively, after 4, 8, and 16 mg.",Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12412821/),%,38,103127,DB00399,Zoledronate
,12412821,Ae0-24 h,"Urinary excretion of zoledronic acid was independent of infusion duration, dose, or number of doses, showing average Ae0-24 h of 38% +/- 13%, 41% +/- 14%, and 37% +/- 17%, respectively, after 4, 8, and 16 mg.",Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12412821/),%,41,103128,DB00399,Zoledronate
,12412821,Ae0-24 h,"Urinary excretion of zoledronic acid was independent of infusion duration, dose, or number of doses, showing average Ae0-24 h of 38% +/- 13%, 41% +/- 14%, and 37% +/- 17%, respectively, after 4, 8, and 16 mg.",Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12412821/),%,37,103129,DB00399,Zoledronate
,12412821,Renal clearance (Ae0-24 h)/(AUC0-24 h),"Renal clearance (Ae0-24 h)/(AUC0-24 h) was on average 69 +/- 28,81 +/- 40, and 54 +/- 34 ml/min after 4,8, and 16 mg, respectively, and showed a moderate correlation (r = 0.5; p < 0.001) with creatinine clearance, which was 84 +/- 23, 82 +/- 25, and 80 +/- 40 ml/min for the dose groups at baseline.",Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12412821/),[ml] / [min],69,103130,DB00399,Zoledronate
,12412821,Renal clearance (Ae0-24 h)/(AUC0-24 h),"Renal clearance (Ae0-24 h)/(AUC0-24 h) was on average 69 +/- 28,81 +/- 40, and 54 +/- 34 ml/min after 4,8, and 16 mg, respectively, and showed a moderate correlation (r = 0.5; p < 0.001) with creatinine clearance, which was 84 +/- 23, 82 +/- 25, and 80 +/- 40 ml/min for the dose groups at baseline.",Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12412821/),[ml] / [min],81,103131,DB00399,Zoledronate
,12412821,Renal clearance (Ae0-24 h)/(AUC0-24 h),"Renal clearance (Ae0-24 h)/(AUC0-24 h) was on average 69 +/- 28,81 +/- 40, and 54 +/- 34 ml/min after 4,8, and 16 mg, respectively, and showed a moderate correlation (r = 0.5; p < 0.001) with creatinine clearance, which was 84 +/- 23, 82 +/- 25, and 80 +/- 40 ml/min for the dose groups at baseline.",Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12412821/),[ml] / [min],54,103132,DB00399,Zoledronate
,32871420,extraction recovery,The extraction recovery varied from 75.4 to 88.0 %.,Rapid and sensitive determination of four bisphosphonates in rat plasma after MTBSTFA derivatization using liquid chromatography-mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32871420/),%,75.4 to 88.0,131338,DB00399,Zoledronate
,21147688,plasma concentration,Mean (standard deviation) plasma concentration of odanacatib was 511.7 (202.9) nM; the range was 63.7-844.8 nM.,"The cathepsin K inhibitor odanacatib suppresses bone resorption in women with breast cancer and established bone metastases: results of a 4-week, double-blind, randomized, controlled trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21147688/),nM,511.7,171082,DB00399,Zoledronate
,21718936,T(1/2α),"Kinetics of blood clearance in mice showed that T(1/2α) and T(1/2β) of (99m)Tc-IPrDP were 1.47 min and 46.47 min, while those of (99m)Tc-ZL were 2.28 and 52.63 min respectively.",Preparation and in vivo biological investigations on a novel radioligand for bone scanning: technetium-99m-labeled zoledronic acid derivative. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21718936/),min,1.47,176312,DB00399,Zoledronate
,21718936,T(1/2α),"Kinetics of blood clearance in mice showed that T(1/2α) and T(1/2β) of (99m)Tc-IPrDP were 1.47 min and 46.47 min, while those of (99m)Tc-ZL were 2.28 and 52.63 min respectively.",Preparation and in vivo biological investigations on a novel radioligand for bone scanning: technetium-99m-labeled zoledronic acid derivative. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21718936/),min,2.28,176313,DB00399,Zoledronate
,21718936,T(1/2β),"Kinetics of blood clearance in mice showed that T(1/2α) and T(1/2β) of (99m)Tc-IPrDP were 1.47 min and 46.47 min, while those of (99m)Tc-ZL were 2.28 and 52.63 min respectively.",Preparation and in vivo biological investigations on a novel radioligand for bone scanning: technetium-99m-labeled zoledronic acid derivative. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21718936/),min,46.47,176314,DB00399,Zoledronate
,21718936,T(1/2β),"Kinetics of blood clearance in mice showed that T(1/2α) and T(1/2β) of (99m)Tc-IPrDP were 1.47 min and 46.47 min, while those of (99m)Tc-ZL were 2.28 and 52.63 min respectively.",Preparation and in vivo biological investigations on a novel radioligand for bone scanning: technetium-99m-labeled zoledronic acid derivative. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21718936/),min,52.63,176315,DB00399,Zoledronate
,26508267,bioavailability,The bioavailability of zoledronate was 55% after intrapulmonary administration in rats.,Pharmacokinetic and therapeutic efficacy of intrapulmonary administration of zoledronate for the prevention of bone destruction in rheumatoid arthritis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26508267/),%,55,228706,DB00399,Zoledronate
,30297386,AUC0-6h,"The levels of AUC0-6h ZA in plasma at week 0 in every (q) 4 and q12 weekly arms of OPTIMIZE-2 were 0.366 h × mg/L and 0.397 h × mg/L compared with 0.345 h × mg/L and 0.356 h × mg/L in CZOL4460503 and CZOL4460506, respectively.",Indirect Evaluation of Bone Saturation with Zoledronic Acid After Long-Term Dosing. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30297386/),[h·mg] / [l],0.366,243825,DB00399,Zoledronate
,30297386,AUC0-6h,"The levels of AUC0-6h ZA in plasma at week 0 in every (q) 4 and q12 weekly arms of OPTIMIZE-2 were 0.366 h × mg/L and 0.397 h × mg/L compared with 0.345 h × mg/L and 0.356 h × mg/L in CZOL4460503 and CZOL4460506, respectively.",Indirect Evaluation of Bone Saturation with Zoledronic Acid After Long-Term Dosing. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30297386/),[h·mg] / [l],0.397,243826,DB00399,Zoledronate
,30297386,AUC0-6h,"The levels of AUC0-6h ZA in plasma at week 0 in every (q) 4 and q12 weekly arms of OPTIMIZE-2 were 0.366 h × mg/L and 0.397 h × mg/L compared with 0.345 h × mg/L and 0.356 h × mg/L in CZOL4460503 and CZOL4460506, respectively.",Indirect Evaluation of Bone Saturation with Zoledronic Acid After Long-Term Dosing. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30297386/),[h·mg] / [l],0.345,243827,DB00399,Zoledronate
,30297386,AUC0-6h,"The levels of AUC0-6h ZA in plasma at week 0 in every (q) 4 and q12 weekly arms of OPTIMIZE-2 were 0.366 h × mg/L and 0.397 h × mg/L compared with 0.345 h × mg/L and 0.356 h × mg/L in CZOL4460503 and CZOL4460506, respectively.",Indirect Evaluation of Bone Saturation with Zoledronic Acid After Long-Term Dosing. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30297386/),[h·mg] / [l],0.356,243828,DB00399,Zoledronate
,30297386,AUC0-6h,"In OPTIMIZE-2, the AUC0-6h ZA plasma levels were the same (0.428 h × mg/L) at week 36 in both q4 and q12 arms.",Indirect Evaluation of Bone Saturation with Zoledronic Acid After Long-Term Dosing. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30297386/),[h·mg] / [l],0.428,243829,DB00399,Zoledronate
,24285189,maximum uptake,The biodistribution in mice shows that (99m)Tc-BIPeDP has high specificity in the skeleton with the maximum uptake of 17.30 ± 0.14 injected dose per gram at 60 min.,Synthesis and pharmacological evaluation of 99mTc-labeled imidazolyl-containing diphosphonic acid as a novel bone imaging agent. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24285189/),[dose·injected] / [gram],17.30,261072,DB00399,Zoledronate
,24285189,distribution half-life (T1/2α),"Kinetics of blood clearance shows that the distribution half-life (T1/2α) and elimination half-life (T1/2β) of (99m)Tc-BIPeDP are 3.7 and 49.7 min, respectively.",Synthesis and pharmacological evaluation of 99mTc-labeled imidazolyl-containing diphosphonic acid as a novel bone imaging agent. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24285189/),min,3.7,261073,DB00399,Zoledronate
,24285189,elimination half-life (T1/2β),"Kinetics of blood clearance shows that the distribution half-life (T1/2α) and elimination half-life (T1/2β) of (99m)Tc-BIPeDP are 3.7 and 49.7 min, respectively.",Synthesis and pharmacological evaluation of 99mTc-labeled imidazolyl-containing diphosphonic acid as a novel bone imaging agent. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24285189/),min,49.7,261074,DB00399,Zoledronate
